1.0君实生物/en/js3333线路检测中心(中国)有限公司-Baidu百科rich600338
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab in Combination with Axitinib for the First-line Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma
/wp-content/uploads/2023/07/微信图片_20230710184607-1.jpg16311087北SHANGHAI, China, July 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with axitinib for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma (“RCC”), has been accepted by the National Medical Products Administration (“NMPA”).